Table 1.
Effects of 25(OH)D and 1,25(OH)2D treatments on human adipocyte differentiation and adipogenesis.
| Cell Type | Type of Vitamin D, Dose, Duration | Results |
|---|---|---|
| hASCs derived from women with normal BMI [30] | 1,25(OH)2D3, 10 nM, 7 and 14 days | - Increased the expression of FABP4, FASN, and PPAR-γ mRNA - Increased ACC, FABP4, and FASN protein levels - Promoted lipid accumulation |
| Human subcutaneous preadipocytes derived from obese men and women [24] | 1,25(OH)2D3, 0.1 and 10 nM, 14 days | - Increased the expression of PPAR-γ and LPL mRNA - Increased FABP protein levels - Increased triglyceride accumulation |
| Human subcutaneous preadipocytes derived from obese men and women [24] | 25(OH)D3, 1 and 10 nM, 14 days | - Increased the expression of LPL mRNA - Increased FABP4 protein levels - Increased triglyceride accumulation |
1,25 (OH)2D3: 1,25-dihydroxyvitamin D3; 25(OH)D3: 25-hydroxyvitamin D3; ACC: acetyl-CoA carboxylase; BMI: body mass index; FABP4: fatty acid-binding protein 4; FASN: fatty acid synthase; hASCs: human adipose-derived stem cells; LPL: lipoprotein lipase; PPAR-γ peroxisome proliferator-activated receptor γ.